Prelude CMO granted 450,000 stock options
Prelude Therapeutics Inc reported that Chief Medical Officer Charles Q. Morris received an employee stock option grant covering 450,000 shares of common stock at an exercise price of $4.70 per share.
Rhea-AI Filing Summary
Prelude Therapeutics Inc reported that Chief Medical Officer Charles Q. Morris received an employee stock option grant covering 450,000 shares of common stock at an exercise price of $4.70 per share.
The option vests 25% on May 1, 2027, then 1/48 of the total shares monthly until fully vested, contingent on continued service. The option expires on April 30, 2036, and all 450,000 options are reported as held directly following this grant.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 450,000 shares
Grant/Award
1 txn
Insider
Morris Charles Q
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 450,000 | $4.70 | $2.12M |
Holdings After Transaction:
Employee Stock Option (right to buy) — 450,000 contracts (Direct)
Footnotes (1)
- F1. The stock option vests as to 25% of the total shares on May 1, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Key Figures
Option grant size: 450,000 shares
Exercise price: $4.70 per share
Post-grant derivative holdings: 450,000 options
+2 more
5 metrics
Option grant size
450,000 shares
Employee stock option underlying common stock
Exercise price
$4.70 per share
Employee stock option strike price
Post-grant derivative holdings
450,000 options
Total options held following this grant
Initial vesting date
May 1, 2027
25% of total option shares vest
Expiration date
April 30, 2036
Stock option expiration
Key Terms
Employee Stock Option (right to buy), exercise price, vesting, expiration date
4 terms
Employee Stock Option (right to buy) financial
"security_title: Employee Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price of $4.7000 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The stock option vests as to 25% of the total shares on May 1, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date set to April 30, 2036 for the option"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Prelude Therapeutics (PRLD) disclose in this Form 4 filing?
Prelude Therapeutics disclosed that Chief Medical Officer Charles Q. Morris received an employee stock option grant for 450,000 shares at a $4.70 exercise price. The filing records this as a compensation-related acquisition, with all granted options held directly after the transaction.
How many Prelude Therapeutics stock options were granted to the CMO?
The Chief Medical Officer received an employee stock option grant covering 450,000 underlying shares of common stock. These options give the right to buy Prelude Therapeutics shares at a fixed $4.70 exercise price, subject to the specific vesting schedule and continued service conditions described in the filing.
What is the exercise price of the new Prelude Therapeutics stock options?
The newly granted employee stock options have an exercise price of $4.70 per share. This means the holder can purchase Prelude Therapeutics common stock at $4.70 once the options vest, provided the options have not expired or been forfeited under the grant’s terms.
When do the Chief Medical Officer’s Prelude Therapeutics options vest?
The options vest 25% of the total shares on May 1, 2027, then 1/48 of the total shares monthly until fully vested. Vesting is contingent on the reporting person continuing to provide service to Prelude Therapeutics on each applicable vesting date, as described in the footnote.
When do the newly granted Prelude Therapeutics stock options expire?
The employee stock options granted to the Chief Medical Officer expire on April 30, 2036. After that expiration date, any unexercised options become worthless, so the holder must exercise vested options before that date if they choose to use them.
Is the Form 4 transaction a market purchase or a compensation grant at Prelude Therapeutics?
The Form 4 records a compensation-related grant, not a market purchase. The transaction is coded as an acquisition of derivative securities (employee stock options) awarded to the Chief Medical Officer, reflecting a grant or award rather than an open-market buy or sell of existing shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
